multi-CAR-T cell therapy
/ SZGIMI
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 19, 2026
Multi-CAR-T Cells Targeting B Cell Lymphomas
(clinicaltrials.gov)
- P1/2 | N=11 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2023 ➔ Dec 2030 | Trial primary completion date: Jul 2023 ➔ Dec 2029
Trial completion date • Trial primary completion date • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • ANPEP • CD19 • CD22 • CD70 • CD79B
June 12, 2020
Multi-CAR-T Cells Targeting B Cell Lymphomas
(clinicaltrials.gov)
- P1/2; N=11; Recruiting; Sponsor: Shenzhen Geno-Immune Medical Institute
CAR T-Cell Therapy • New P1/2 trial • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
1 to 2
Of
2
Go to page
1